Value-Based Care Solution for Early Sarcoma Detection
SarcRisk API
Empowering primary care physicians to identify sarcoma risk earlier through data-driven insights, reducing diagnostic delays that drop survival rates from 80% when caught early to just 16% at Stage IV.
We’re currently raising our pre-seed round. Interested in investing or learning more?
[Email the Founder]
AnnieGuard’s technology — including the SarcRisk API and its underlying clinical logic — is protected by a provisional patent filing. This covers the use of proprietary biomarkers and AI-powered risk assessment methods for early sarcoma detection. All product designs, algorithms, and materials are proprietary and confidential. Unauthorized use, replication, or reverse engineering is strictly prohibited. To request demo access or partnership details, please contact us directly. Additional information may be available under NDA.